Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 5/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332131 | 0.89 | SCN9A (0.49) | SCN9AAOC3ABL1CHEK2CYP3A4 | |
| SCHEMBL4491094 | 0.88 | SCN9A (0.59) | SCN9AAOC3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5001287 | 0.83 | AOC3 (0.43) | SCN9AAOC3 | |
| SCHEMBL4320150 | 0.83 | AOC3 (0.40) | SCN9AAOC3CHEK2 | |
| SCHEMBL4321753 | 0.82 | AOC3 (0.38) | SCN9AAOC3ABL1 | |
| SCHEMBL4483669 | 0.82 | SCN9A (0.56) | SCN9ACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4327442 | 0.81 | SCN9A (0.50) | SCN9AAOC3ABL1CYP3A4CYP2D6 | |
| SCHEMBL4323190 | 0.81 | CHEK2 (0.42) | SCN9AAOC3CHEK2 | |
| SCHEMBL4320132 | 0.81 | SCN9A (0.48) | SCN9AAOC3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13913158 | 0.81 | ADORA2A (0.42) | SCN9AAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1694654-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2005047270-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | TRPV1, SCN3A, SCN5A | SCN9A 50/4885AOC3 2903/4885ABL1 2236/4885 |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | TRPV1, SCN3A, SCN5A | SCN9A 50/4885AOC3 3035/4885ABL1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.